<DOC>
	<DOCNO>NCT02298283</DOCNO>
	<brief_summary>This study aim evaluate efficacy brentuximab vedotin consolidation treatment patient stage I/II Hodgkin 's lymphoma 18-fluorodeoxyglucose ( FDG ) -PET positivity 2 cycle ABVD ( adriamycin , bleomycin , vinblastine , dacarbazine ) .</brief_summary>
	<brief_title>Brentuximab Vedotin Consolidation Treatment Patients With Stage I/II HL PET Positivity After 2 Cycles ABVD</brief_title>
	<detailed_description>This study aim evaluate progression free survival treatment patient stage I/II supradiaphragmatic HL patient PET positive 2 course ABVD . The treatment consist 3 phase : - induction treatment 2 cycle every 3 week bleomycin , etoposide , Adriamycin , cyclophosphamide , oncovin , procarbazine , prednisone ( BEACOPP ) escalate - radiotherapy 30 Gy start 3 4 week last day second course BEACOPP-escalated - consolidation treatment 8 cycle every 21 day brentuximab vedotin</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients must histologically confirm cluster differentiation antigen 30+ ( CD30+ ) classical Hodgkin lymphoma 2 . Patients must provide voluntary write informed consent 3 . Supradiaphragmatic Ann Arbor clinical stage I II 4 . Mandatory PET scan perform diagnosis 5 . Patients treat firstline ABVD PET scan positive 2 cycle ( Deauville score 4 &amp; 5 ) 6 . Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 02 7 . Life expectancy &gt; 6 month 8 . Patients must 1865 year age 9 . Patients must available periodic blood sampling , studyrelated assessment management toxicity treat institution 10 . Female patient : Are postmenopausal least 1 year screen visit OR surgically sterile OR If childbearing potential , agree practice 2 effective method contraception time 11 . Male patient , even surgically sterilize , agree practice effective barrier contraception entire study treatment period 6 month last dose study drug , agree completely abstain heterosexual intercourse 12 . Clinical laboratory value specify first dose study drug : Absolute neutrophil count ≥ 1,500/µL Platelet count ≥ 75,000/ µL Total bilirubin must &lt; 1.5 x upper limit normal ( ULN ) unless elevation know due Gilbert syndrome Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) must &lt; 3 x upper limit normal range Serum creatinine must &lt; 2.0 mg/dL and/or creatinine clearance calculate creatinine clearance &gt; 40 mL/minute Hemoglobin must ≥ 8g/dL 13 . Patient affiliate social security system 1 . Patients dementia alter mental status would preclude compliance drug delivery 2 . Women pregnant breastfeed 3 . Patients symptomatic pulmonary disease 4 . Patients known history follow cardiovascular condition : Myocardial infarction within 2 year inclusion New York Heart Association ( NYHA ) Class III IV heart failure Evidence current uncontrolled cardiovascular condition , include cardiac arrhythmia , congestive heart failure ( CHF ) , angina , electrocardiographic evidence acute ischemia active conduction system abnormalities Recent evidence ( within 6 month first dose study drug ) leftventricular ejection fraction &lt; 50 % 5 . Any history cancer cancer treatment last 3 year exception nonmelanoma skin cancer stage 0 ( situ ) carcinoma type undergone complete resection 6 . Uncontrolled infectious disease , include active Hepatitis B Virus ( HBV ) infection define either detection Hepatitis B surface ( HBs ) Antigen presence Hepatitis B core ( HBc ) antibody without detectable anti HBs antibody 7 . Any active systemic viral , bacterial , fungal infection require systemic antibiotic time inclusion plan still go within 2 week prior first study drug dose 8 . Known Human Immunodeficiency Virus ( HIV ) , know suspect hepatitis C Virus ( HCV ) human Tcell lymphotrophic virus ( HTLV ) serology positivity 9 . Patients treat previously antiCD30 antibody 10 . Known hypersensitivity excipients contain brentuximab vedotin formulation 11 . Known cerebral meningeal disease ( HL etiology ) , include sign symptom Progressive Multifocal Leukoencephalopathy ( PML ) 12 . Any sensory motor peripheral neuropathy great equal Grade 2 13 . Patients complete prior treatment chemotherapy and/or investigational agent within least 5 halflives last dose prior treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hodgkin lymphoma</keyword>
	<keyword>HL</keyword>
	<keyword>brentuximab vedotin</keyword>
</DOC>